Expression of p53 protein as a prognostic factor in patients with gastric cancer

European Journal of Cancer

Volumn 32, Issue 2, 1996, Pages 215-220

  Victorzon, M ^a   Nordling, S ^a   Haglund, C ^a   Lundin, J ^a   Roberts, P J ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Gastric cancer; Immunoreactivity; P53; Prognosis; Tumour suppressor gene protein

Indexed keywords

MONOCLONAL ANTIBODY;

ADENOCARCINOMA; ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUTATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0043042253     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00547-1     Document Type: Article

References (40)

1. Lane DP, Crawford LV. T antigen is bound to a host protein in SV40 transformed cells. Nature 1979, 278, 261-263.
2. Parada LF, Land H, Weinberg RA, Wolf D, Rotter V. Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature 1984, 312, 649-651.
3. Finlay CA, Hinds PW, Levine AJ. The proto-oncogene p53 can act as a suppressor of transformation. Cell 1989, 57, 1083-1093.
4. Lane DP, Benchimol S. Oncogene or anti-oncogene? Genes Dev 1990, 4, 1-8.
5. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993, 9, 138-141.
6. Nigro JM, Baker SJ, Preisinger ACea. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989, 342, 705-708.
7. Bartek J, Bartkova J, Vojtesek B, et al. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 1991, 6, 1699-1703.
8. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991, 253, 49-53.
9. Lane DP. p53, guardian of the genome. Nature 1992, 358, 15-16.
10. Hunter T. Braking the cycle. Cell 1993, 75, 839-841.
11. Symonds H, Krall L, Remington L, et el. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 1994, 78, 703-711.
12. Isobe M, Emanuel BS, Girol D, Oren M, Croce CM. Localization of gene for human p53 tumour antigen to band 17p13. Nature 1986, 320, 84-95.
13. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993, 329, 1318-1327.
14. Dowell SP, Hall PA. The clinical relevance of the p53 tumour suppressor gene. Cytopathology 1994, 5, 133-145.
15. Martin HM, Filipe MI, Morris RW, Lane DP, Silvestre F. p53 expression and prognosis in gastric carcinoma. Int J Cancer 1992, 50, 859-862.
16. Seruca R, David L, Holm R, et al. P53 mutations in gastric carcinomas. Br J Cancer 1992, 65, 708-710.
17. Joypaul BV, Hopwood D, Newman EL, et al. The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocarcinoma. Br J Cancer 1994, 69, 943-946.
18. Starzynska T, Bromley M, Ghosh A, Stern PL. Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer 1992, 66, 558-562.
19. Kakeji Y, Korenaga D, Tsujitani S, et al. Gastric cancer with p53 overexpression has high potential for metastasising to lymph nodes. Br J Cancer 1993, 67, 589-593.
20. Yonemura Y, Fushida S, Tsugawa K, et al. Correlation of p53 expression and proliferative activity in gastric cancer. Ann Cell Pathol 1993, 5, 277-288.
21. Laurén P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinomas: an attempt at a histological classification. Acta Pathol Microbiol Scand 1965, 64, 31-49.
22. Boguslawsky K von. Immunohistochemical detection of progesterone receptors in paraffin sections. A novel method using microwave oven pretreatment. Apmis 1994, 102, 641-646.
23. Cox DR. Regression models and life tables. JR Stat Soc 1972, B34, 187-220.
24. Uchino S, Noguchi M, Ochiai A, Saito T, Kobayashi M, Hirohashi S. p53 mutation in gastric cancer: a genetic model for carcinogenesis is common to gastric and colorectal cancer. Int J Cancer 1993, 54, 759-764.
25. Fukunaga M, Monden T, Nakanishi H, et al. Immunohistochemical study of p53 in gastric carcinoma. Am J Clin Pathol 1994, 101, 177-180.
26. Scarpa A, Capelli P, Mukai K, et al. Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol 1993, 142, 1534-1543.
27. Hayashi N, Ito I, Yanagisawa A, et al. Genetic diagnosis of lymph-node metastasis in colorectal cancer. Lancet 1995, 345, 1257-1259.
28. Isola J, Visakorpi T, Holli K, Kallioniemi OP. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 1992, 84, 1109-1114.
29. Visakorpi T, Kallioniemi OP, Heikkinen A, Koivula T, Isola J. Small subgroup of aggressive, highly proliferative prostatic carcinomas denned by p53 accumulation. J Natl Cancer Inst 1992, 84, 883-887.
30. Barnes D, Dublin E, Fisher C, Levison D, Millis R. Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Human Pathol 1993, 24, 469-476.
31. Lipponen P, Ji H, Aaltomaa S, Syrjanen S, Syrjanen K. p53 protein expression in breast cancer as related to histopathological characteristics and prognosis. Int J Cancer 1993, 55, 51-56.
32. Sarkis AS, Dalbagni G, Cordon Cardo C, et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 1993, 85, 53-59.
33. Scott N, Sagar P, Stewart J, Blair GE, Dixon MF, Quirke P. p53 in colorectal cancer: clinicopathological correlation and prognostic significance. Br J Cancer 1991, 63, 317-319.
34. Gitsch G, Kainz C, Joura E, Breitenecker G. Mutant p53 product in patients with stage III cervical cancer. Anticancer Res 1992, 12, 2241-2242.
35. McLaren R, Kuzu I, Dunnill M, Harris A, Lane D, Gatter KC. The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 1992, 66, 735-738.
36. Sun XF, Carstensen JM, Zhang H, et al. Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet 1992, 340, 1369-1373.
37. Quinlan DC, Davidson AG, Summers CL, Warden HE, Doshi HM. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 1992, 52, 4828-4831.
38. Yamaguchi A, Kurosaka Y, Fushida S, et al. Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis. Cancer 1992, 70, 2778-2784.
39. Bell S, Scott N, Cross D, et al. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology 1993, 104, 57-64.
40. Horio Y, Takahashi T, Kuroishi T, et al. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 1993, 53, 1-4.